Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection

被引:57
|
作者
Wolff, Bruce G.
Weese, James L.
Ludwig, Kirk A.
Delaney, Conor P.
Stamos, Michael J.
Michelassi, Fabrizio
Du, Wei
Techner, Lee
机构
[1] Mayo Clin, Coll Med, Div Colon & Rectal Surg, Rochester, MN 55905 USA
[2] Univ Med & Dent New Jersey, Stratford, NJ USA
[3] Duke Med Ctr, Sect Gastrointestinal Surg, Durham, NC USA
[4] Univ Hosp Cleveland, Div Colorectal Surg, Cleveland, OH 44106 USA
[5] Univ Calif Irvine, Dept Surg, Irvine, CA 92717 USA
[6] Adolor Corp, Exton, PA USA
[7] Cornell Univ, Weill Med Coll, Dept Surg, New York, NY USA
关键词
D O I
10.1016/j.jamcollsurg.2007.01.041
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Postoperative ileus (POI), an interruption of coordinated bowel motility after operation, is exacerbated by opioids used to manage pain. Alvimopan, a peripherally acting mu-opioid receptor antagonist, accelerated gastrointestinal (GI) recovery after bowel resection in randomized, double-blind, placebo-controlled, multicenter phase III POI trials. The effect of alvimopan on POI-related morbidity for patients who underwent bowel resection was evaluated in a post-hoc analysis. STUDY DESIGN: Incidence of POI-related postoperative morbidity (postoperative nasogastric tube insertion or POI-related prolonged hospital stay or readmission) was analyzed in four North American trials for placebo or alvimopan 12 mg administered 30 minutes or more preoperatively and twice daily postoperatively until hospital discharge (7 or fewer postoperative days). GI-related adverse events and opioid consumption were summarized for each treatment. Estimations of odds ratios of alvimopan to placebo and number needed to treat (NNT) to prevent one patient from experiencing an event of POI-related morbidity were derived from the analysis. RESULTS: Patients receiving alvimopan 12 mg were less likely to experience POI-related morbidity than patients receiving placebo (odds ratio = 0.44, p < 0.001). Fewer patients receiving alvimopan (alvimopan, 7.6%; placebo, 15.8%; NNT = 12) experienced POI-related morbidity There was a lower incidence of postoperative nasogastric tube insertion, and other GI-related adverse events on postoperative days 3 to 6 in the alvimopan group than the placebo group. Opioid consumption was comparable between groups. CONCLUSIONS: Alvimopan 12 mg was associated with reduced POI-related morbidity compared with placebo, without compromising opioid-based analgesia in patients undergoing bowel resection. Relatively low NNTs are clinically meaningful and reinforce the potential benefits of alvimopan for the patient and health care system. (J Am Coll Surg 2007;204:609-616. (C) 2007 by the American College of Surgeons).
引用
收藏
页码:609 / 616
页数:8
相关论文
共 50 条
  • [1] Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients
    Janice Jang
    Benjamin Kwok
    Hua Zhong
    Yuhe Xia
    Alexis Grucela
    Mitchell Bernstein
    Feza Remzi
    David Hudesman
    Jingjing Chen
    Jordan Axelrad
    Shannon Chang
    Digestive Diseases and Sciences, 2020, 65 : 1164 - 1171
  • [2] Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients
    Jang, Janice
    Kwok, Benjamin
    Zhong, Hua
    Xia, Yuhe
    Grucela, Alexis
    Bernstein, Mitchell
    Remzi, Feza
    Hudesman, David
    Chen, Jingjing
    Axelrad, Jordan
    Chang, Shannon
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (04) : 1164 - 1171
  • [3] Alvimopan for the Management of Postoperative Ileus After Bowel Resection: Characterization of Clinical Benefit by Pooled Responder Analysis
    Ludwig, Kirk
    Viscusi, Eugene R.
    Wolff, Bruce G.
    Delaney, Conor P.
    Senagore, Anthony
    Techner, Lee
    WORLD JOURNAL OF SURGERY, 2010, 34 (09) : 2185 - 2190
  • [4] Alvimopan for the Management of Postoperative Ileus After Bowel Resection: Characterization of Clinical Benefit by Pooled Responder Analysis
    Kirk Ludwig
    Eugene R. Viscusi
    Bruce G. Wolff
    Conor P. Delaney
    Anthony Senagore
    Lee Techner
    World Journal of Surgery, 2010, 34 : 2185 - 2190
  • [5] Alvimopan, for postoperative ileus following bowel resection - A pooled analysis of phase III studies
    Delaney, Conor P.
    Wolff, Bruce G.
    Viscusi, Eugene R.
    Senagore, Anthony J.
    Fort, John G.
    Du, Wei
    Techner, Lee
    Wallin, Bruce
    ANNALS OF SURGERY, 2007, 245 (03) : 355 - 363
  • [6] The Use of Alvimopan as Prophylaxis against Post-Operative Ileus After Bowel Resection in Patients With Inflammatory Bowel Disease
    Janice, Jang
    Benjamin, Kwok
    Alexis, Grucela
    Mitchell, Bernstein
    Feza, Remzi
    David, Hudesman
    Chen Jingjing
    Shannon, Chang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1 - S2
  • [7] THE USE OF ALVIMOPAN AS PROPHYLAXIS AGAINST POST-OPERATIVE ILEUS AFTER BOWEL RESECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Jang, Janice
    Kwok, Benjamin
    Zhong, Hua
    Xia, Yuhe
    Grucela, Alexis
    Bernstein, Mitchell
    Remzi, Feza H.
    Hudesman, David
    Chen, Jingjing
    Axelrad, Jordan E.
    Chang, Shannon
    GASTROENTEROLOGY, 2019, 156 (06) : S662 - S662
  • [8] The use of alvimopan for postoperative ileus in small and large bowel resections
    Brady, Justin T.
    Dosokey, Eslam M. G.
    Crawshaw, Benjamin P.
    Steele, Scott R.
    Delaney, Conor P.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (11) : 1351 - 1358
  • [9] Effect of Alvimopan on Postoperative Ileus and Length of Hospital Stay in Patients Undergoing Bowel Resection: A Systematic Review and Meta-Analysis
    Murtaza, Rashid
    Clarke, Olivia
    Sivakanthan, Tharshan
    Al-Sarireh, Hashim
    Al-Sarireh, Ahmad
    Raza, Muhammad Musa
    Navid, Ahmad Zia
    Ali, Baqar
    Hajibandeh, Shahin
    Hajibandeh, Shahab
    AMERICAN SURGEON, 2024, 90 (12) : 3272 - 3283
  • [10] Effect of alvimopan (ALV) on gastrointestinal (GI) recovery, length of hospital stay (LOS), and postoperative ileus (POI)-related morbidity in patients (PTS) undergoing bowel resection (BR) for colon or rectal cancer (CRC)
    Weese, J. L.
    Du, W.
    Techner, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)